What happens if unproven stem cell clinic firms like GIOSTAR start getting okays from the FDA to do clinical trials? On the one hand, it could reflect a positive trend of stem cell clinic firms working with the FDA and toward compliance. Having more robust data. However, I worry about some of these types of […]
It’s been a long saga for the FDA and the unproven stem cell clinic group called Cell Surgical Network, headquartered in Beverly Hills. A court case involving the two has been unfolding for many years. It has big implications for agency authority and the hundreds of stem cell clinics across the U.S. The case took
After a bit of a hiatus in 2024, our list of regenerative medicine and stem cell meetings returns for 2025. I’m noticing a lot of great stem cell meetings already scheduled for 2025. With the pandemic being less of an ever-present thing, most meetings are now only in-person these days. In a way, the hybrid
2025 regenerative medicine and stem cell meetings list Read More »
Is there a proven stem cell therapy for vision loss? When I started The Niche back in early 2010, one major area of hope was that there might one day be a stem cell therapy for vision loss or even blindness. Maybe even a cure for blindness. While we’re not there yet as a field,
What are the most significant stem cell and regenerative medicine good news stories of 2024? Since it has been an eventful year, there are many possibilities. Please see our poll at the bottom of this post and weigh in on what you think is the most important encouraging news. If you don’t see your choice
Poll on stem cell & regenerative medicine good news of 2024 Read More »
As we look to 2025, what are the best regenerative medicine and stem cell journals? Is there a stem cell journal list out there? I seem to have the only comprehensive list. Who better than a stem cell biologist to put together this kind of list? Why is this important? Scientists need to know what
List of regenerative medicine & stem cell journals Read More »
Cancer stem cells are stem cell-like cells in many tumors that are key contributors to the ability of tumors to persist and recur after treatment. For those reasons, they are also thought to be major targets, including of emerging therapies. Data also suggest that some therapies may create new types of cancer stem cells leading
Weekly reads: cancer stem cells, encouraging findings, Trump & NIH, proteomics Read More »
The cell therapy biotech Capricor recently released new data from their Duchenne Muscular Dystrophy (DMD) trial work. The data have generated excitement in the patient advocacy community. The stock has skyrocketed. How exciting are these new data? CEO Linda Marbán is quite upbeat and I think it’s justified. The firm is now seeking FDA approval
Capricor seeks FDA approval of deramiocel for Duchenne based on encouraging data Read More »
For a few years, biophysicist He Jiankui might have been one of the most recognizable scientists on the planet. He made three “CRISPR babies” or gene edited people. However, his gene editing went badly and as best as we can tell his efforts did not result in precision edits. It’s unclear if he had institutional
What do patients who go to stem cell clinics really think of their experiences? It can be hard to get good data on this important question. For that reason, it was great to see a new article on this topic. With perhaps around 2,000 unproven clinics in the U.S., these firms are likely to have